Navigation Links
NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Date:1/3/2008

SOPHIA ANTIPOLIS, France, Jan. 3 /PRNewswire/ -- NicOx S.A. (Euronext Paris: COX) today announced that Pfizer Inc (NYSE: PFE) has initiated a dose-ranging phase 2 clinical study for PF-03187207 in Japan. PF-03187207 is a new experimental medicine for the treatment of glaucoma, which is currently in an ongoing phase 2 proof-of-concept study in the United States (see press releases of March 28 and 29, 2007). Glaucoma and ocular hypertension are a group of severe eye diseases that can lead to blindness and this new Japanese study will compare the safety and efficacy of PF-03187207 to Xalatan(R) (latanoprost) in Japanese patients with these conditions. Xalatan(R) is a proprietary Pfizer product and the leader in worldwide glaucoma sales, with approximately $1.5 billion of franchise sales in 2006.

PF-03187207 is the lead development compound generated under the August 2004 collaboration agreement between Pfizer and NicOx, which focuses on the research and development of nitric oxide-donating prostaglandin F2-alpha analogs for the treatment of glaucoma (see NOTE).

Maarten Beekman, Vice President of Clinical Development at NicOx, said: "We believe the initiation of this separate Japanese study for PF-03187207 highlights Pfizer's determination to rapidly advance this clinical program towards coordinated regulatory filing in the world's major pharmaceutical markets. Preclinical results have suggested that NicOx' technology has the potential to deliver improved treatments for glaucoma and we look forward to the results of the ongoing proof-of-concept phase 2 study for PF-03187207 in the United States."

Design and rationale for the study

The first clinical study for PF-03187207, initiated in March 2007 in the United States
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2014)... , July 27, 2014 /PRNewswire-iReach/ -- ... survey on Global and Chinese Vardenafil (CAS ... basic information of Vardenafil (CAS 224785-90-4) including ... report then explores global and China,s top ... product specification, capacity, production value, cost, gross ...
(Date:7/25/2014)... -- Smile Train and its technology partner BioDigital have been ... among leading global health innovations in The Hive at ... Washington, D.C. at The John F. Kennedy ... Train is honored to be represented through our partnership ... health and medicine that TEDMED unites each year," said ...
(Date:7/25/2014)... Trinidad and Tobago , July 25, 2014 ... the Trinidad & Tobago Ministry of Health approved ... therapy that significantly increases the cure rate from ... infected with the genotype 1 virus. Telaprevir is ... the trade brand INCIVO®. Photo - ...
Breaking Medicine Technology:Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
... 2010 Telik, Inc. (Nasdaq: TELK ) ... drugs to treat cancer, announced that it has been ... Therapeutic Discovery Project (QTDP).  The grants are intended to ... including the company,s most advanced investigational drug candidate, TELINTRA®, ...
... Nov. 2, 2010 OncoMed Pharmaceuticals, Inc., a ... cells, announced today that it has been awarded ... under the U.S. Government,s Qualifying Therapeutic Discovery Project ... by the company received an award.  The funds ...
Cached Medicine Technology:Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects 2OncoMed Pharmaceuticals Awarded Five Therapeutic Discovery Project Grants Totaling $1.2 Million 2OncoMed Pharmaceuticals Awarded Five Therapeutic Discovery Project Grants Totaling $1.2 Million 3
(Date:7/28/2014)... (PRWEB) July 28, 2014 Termed by ... drug abuse causes more fatal overdoses than heroin and ... year. (1) Those who are particularly vulnerable to succumbing ... and up), with many in this age group taking ... this growing epidemic was reawakened in the White House ...
(Date:7/28/2014)... Freeonlinelifeinsuranceleads.com has released a new blog ... insurance quotes. , Comparing life insurance quotes can help ... costs. Finding affordable coverage is easier online by visiting ... agencies and displays them on a single web page. ... find cheaper coverage, but they can also learn more ...
(Date:7/28/2014)... HealthDay Reporter FRIDAY, July 25, 2014 (HealthDay News) ... blood donations from gay and bisexual men, according to a team ... Journal of the American Medical Association . Currently, a man ... in the United States -- a lifetime ban that has been ... adopted this policy at the dawn of the AIDS crisis. ...
(Date:7/28/2014)... By Dennis Thompson ... -- The U.S. Supreme Court,s ruling on contraception coverage -- ... to a legal quagmire that might allow companies to deny ... principles, some health care experts say. But other experts ... The justices ruled 5-4 last month that Hobby Lobby Stores ...
(Date:7/28/2014)... July 28, 2014 For those with dust ... cause of dust allergies—commonly settle in mattresses, bedding, and upholstered ... , Dust mites are microscopic insects that feed on the ... each day to keep a million dust mites fat and ... high power microscope, the decaying bodies and feces of dust ...
Breaking Medicine News(10 mins):Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 2Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 3Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 4Health News:Comparing Life Insurance Quotes Online Offers 3 Important Advantages! 2Health News:Lift U.S. Ban on Blood Donations by Gay Men, Experts Say 2Health News:Lift U.S. Ban on Blood Donations by Gay Men, Experts Say 3Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 2Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 3Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 4Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 5Health News:AllergyEasy® Announces No-shots Immunotherapy to Mitigate Dust Allergies 2Health News:AllergyEasy® Announces No-shots Immunotherapy to Mitigate Dust Allergies 3
... Present Clinical Data at, ... Upcoming Scientific Meeting -,LAVAL, QC, May ... ) today announced the publication of Extended Release Trazodone in Major ... issue of the journal Psychiatry (Edgemont) (Volume 6, Number 5) ( ...
... German . , When cells cannot carry out ... is disease. Nanobiotechnology researchers are looking for ways to allow ... absent from the cell. This requires transport systems that can ... controlled fashion at the right moment. The transporter must be ...
... Pharmaceutical Research and Manufacturers of America (PhRMA) unveiled a ... for diabetes. The report shows that America,s pharmaceutical research ... diabetes medicines. The medicines listed in the report are ... approval by the U.S. Food and Drug Administration.The report ...
... delivery and glucose sensing leadership INDIANAPOLIS and MINNEAPOLIS, May ... diabetes management -Eli Lilly and Company (NYSE: ... ) - today announced a strategic marketing collaboration to ... manage their blood sugar using insulin therapy.Working collaboratively with ...
... Leading Veterinary Care Digital Imaging and Data Management ... 19 Eklin Medical Systems, a leading provider ... and Communications Systems) and practice management software (VIA(R)) ... Juan Thorn as the company,s West Coast ultrasound ...
... ,sings, could improve our understanding of conditions such as ... at Cardiff University have discovered. , Research by ... Centre (CUBRIC) has discovered that a person,s brain produces ... a person looks at a visual pattern. , ...
Cached Medicine News:Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 2Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 3Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 4Health News:Capsules encapsulated 2Health News:New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes 2Health News:New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes 3Health News:New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes 4Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 2Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 3Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 4Health News:Eklin Medical Systems Appoints Juan Thorn as West Coast Ultrasound Sales Representative 2Health News:'Singing brains' offers epilepsy and schizophrenia clues 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: